Sophie Nicole1, Bertrand Fontaine. 1. aINSERM U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière - ICM bAP-HP, Hôpital de la Pitié-Salpêtrière, Département des Maladies du Système Nerveux, Paris, France.
Abstract
PURPOSE OF REVIEW: This is an update on skeletal muscle sodium channelopathies since knowledge in the field have dramatically increased in the past years. RECENT FINDING: The relationship between two phenotypes and SCN4A has been confirmed with additional cases that remain extremely rare: severe neonatal episodic laryngospasm mimicking encephalopathy, which should be actively searched for since patients respond well to sodium channel blockers; congenital myasthenic syndromes, which have the particularity to be the first recessive Nav1.4 channelopathy. Deep DNA sequencing suggests the contribution of other ion channels in the clinical expressivity of sodium channelopathies, which may be one of the factors modulating the latter. The increased knowledge of channel molecular structure, the quantity of sodium channel blockers, and the availability of preclinical models would permit a most personalized choice of medication for patients suffering from these debilitating neuromuscular diseases. SUMMARY: Advances in the understanding of the molecular structure of voltage-gated sodium channels, as well as availability of preclinical models, would lead to improved medical care of patients suffering from skeletal muscle, as well as other sodium channelopathies.
PURPOSE OF REVIEW: This is an update on skeletal muscle sodium channelopathies since knowledge in the field have dramatically increased in the past years. RECENT FINDING: The relationship between two phenotypes and SCN4A has been confirmed with additional cases that remain extremely rare: severe neonatal episodic laryngospasm mimicking encephalopathy, which should be actively searched for since patients respond well to sodium channel blockers; congenital myasthenic syndromes, which have the particularity to be the first recessive Nav1.4channelopathy. Deep DNA sequencing suggests the contribution of other ion channels in the clinical expressivity of sodium channelopathies, which may be one of the factors modulating the latter. The increased knowledge of channel molecular structure, the quantity of sodium channel blockers, and the availability of preclinical models would permit a most personalized choice of medication for patients suffering from these debilitating neuromuscular diseases. SUMMARY: Advances in the understanding of the molecular structure of voltage-gated sodium channels, as well as availability of preclinical models, would lead to improved medical care of patients suffering from skeletal muscle, as well as other sodium channelopathies.
Authors: Alberto Bergareche; Marcin Bednarz; Elena Sánchez; Catharine E Krebs; Javier Ruiz-Martinez; Patricia De La Riva; Vladimir Makarov; Ana Gorostidi; Karin Jurkat-Rott; Jose Felix Marti-Masso; Coro Paisán-Ruiz Journal: Hum Mol Genet Date: 2015-10-01 Impact factor: 6.150
Authors: Mikhail Yu Myshkin; Roope Männikkö; Olesya A Krumkacheva; Dmitrii S Kulbatskii; Anton O Chugunov; Antonina A Berkut; Alexander S Paramonov; Mikhail A Shulepko; Matvey V Fedin; Michael G Hanna; Dimitri M Kullmann; Elena G Bagryanskaya; Alexander S Arseniev; Mikhail P Kirpichnikov; Ekaterina N Lyukmanova; Alexander A Vassilevski; Zakhar O Shenkarev Journal: Front Pharmacol Date: 2019-09-04 Impact factor: 5.810
Authors: Michele Cavalli; Barbara Fossati; Raffaele Vitale; Elisa Brigonzi; Vito A G Ricigliano; Lorenzo Saraceno; Rosanna Cardani; Carlo Pappone; Giovanni Meola Journal: Front Neurol Date: 2018-05-30 Impact factor: 4.003